Acquisition History QS Pharma was acquired by Quotient Sciences in February 2017 for 75M, highlighting its established CDMO capabilities and potential integration with early-phase development services to offer end-to-end solutions.

Quality with Speed The company markets a Quality with Speed™ approach across early development, preclinical formulations, and clinical/commercial manufacturing, signaling a sales pitch focused on rapid, compliant product progression for biotech and pharma partners.

Mid-Sized CDMO With 51-200 employees and annual revenue in the $10M–$25M range, QS Pharma presents as a nimble, mid-sized partner capable of personalized service, potentially appealing to mid- to late-stage biotech firms seeking flexible development and manufacturing support.

Strategic Focus Areas Capabilities span from NCE screening and toxicology formulations to stable, manufacturable dosage forms and commercial manufacturing, offering opportunities to cross-sell end-to-end development and scale-up services to clients transitioning from discovery to commercialization.

Market Position Operating in a competitive CDMO landscape with peers like Medpace, Parexel, WuXi, and Charles River, QS Pharma can leverage its alliance with Quotient and its emphasis on speed and quality to win business from companies seeking integrated early-phase to manufacturing partnerships.